Skip to main content
 

2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
11/10/16WAVE Life Sciences Appoints Christian Henry to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the appointment of Christian Henry, Executive Vice President & Chief Commercial Officer of Illumina, Inc., to its Board of Directors and as the Chair of its Audit Committee. “The addition of Christian Henry to our Board complements... 
Printer Friendly Version
11/09/16WAVE Life Sciences Reports Third Quarter 2016 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced financial results for the third quarter ended September 30, 2016. “WAVE continued its strong progress this quarter and we are on track to achieve our 2016 corporate goals, including the filing of two INDs in Huntington’s disease,... 
Printer Friendly Version
11/07/16WAVE Life Sciences to Present at the Jefferies 2016 London Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016, at 8:40 A.M. GMT in London, United Kingdom. A live webcast will a... 
Printer Friendly Version
09/14/16WAVE Life Sciences to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
CAMBRIDGE, Mass--(BUSINESS WIRE)--Sep. 14, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will participate in a fireside chat and provide a company overview at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable on Wednesday, September 28, 2016, at 9:0... 
Printer Friendly Version
08/17/16WAVE Life Sciences Appoints Keith Regnante as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 17, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announced that it has appointed Keith Regnante as the company’s Chief Financial Officer. Mr. Regnante will provide strategic direction and bring substantial management experience to WAVE’s finance and operations functions. ... 
Printer Friendly Version
08/15/16WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update
On track to file two INDs for lead programs in Huntington's disease in 2016 and IND for lead program in Duchenne muscular dystrophy in 2017 Current financial position supports continued pipeline progression, six clinical programs by 2018 and operations into 2019 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 15, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today reported fina... 
Printer Friendly Version
07/12/16WAVE Life Sciences Appoints Dr. Michael Panzara as Head of Neurology Franchise
Former Head of Multiple Sclerosis, Neurology, and Ophthalmology at Sanofi Genzyme with 15 years of key leadership roles in neurological drug development to lead advancement of WAVE’s neurology portfolio including neuromuscular, neurodegenerative, and neurosensory indications CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 12, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for ... 
Printer Friendly Version
06/27/16WAVE Life Sciences Added to the Russell 2000® Index
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 27, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Microcap® and the Russell Global® Indexes following this year’s Russell Indexes Reconstitution, effective as of June 27, 2016. The Russell... 
Printer Friendly Version
06/21/16WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
Allele-specific targeting silences mutant HTT allele while leaving healthy HTT allele intact On track to file investigational new drug (IND) application in late 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 21, 2016-- WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announced that its lead candidate WVE-120101, w... 
Printer Friendly Version
06/15/16WAVE Life Sciences to Present at the JMP Securities Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will participate in a fireside chat and provide a company overview at the JMP Securities Life Sciences Conference at 2:30 PM Eastern Time on Tuesday, June 21, 2016 in N... 
Printer Friendly Version
06/01/16WAVE Life Sciences to Present at the Jefferies 2016 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 3:00 PM Eastern Time on Wednesday, June 8, 2016 in New York, NY. A live webcast will also be available on the investor relations page of WA... 
Printer Friendly Version
05/16/16WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update
On track to deliver six clinical programs by 2018, including two IND filings in 2016 Entered collaboration with Pfizer to develop genetically targeted therapies for the treatment of metabolic diseases Existing cash supports pipeline progression, clinical programs and operations into 2019 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on develop... 
Printer Friendly Version
05/09/16WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to Address Unmet Need in Duchenne Muscular Dystrophy
WAVE advances exon 51 DMD candidate; initiation of first clinical trial planned for 2H 2017; candidates for other exons expected to follow Preclinical data demonstrates 25-fold enhanced exon-skipping efficiency and broader distribution, including to heart and diaphragm, compared to other exon-skipping therapies WAVE to present data at upcoming Parent Project Muscular Dystrophy (PPMD) Annual Connect Con... 
Printer Friendly Version
05/05/16WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases
Collaboration will combine WAVE’s proprietary antisense and RNAi capabilities with GalNAc and Pfizer’s hepatic targeting technology for potential development of optimized therapeutics CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2016-- WAVE Life Sciences Ltd. (NASDAQ:WVE) today announced that it has entered into a research, license and option agreement with Pfizer Inc. (NYSE: PFE) for the potential development of nucleic acid therapies aimed at s... 
Printer Friendly Version
04/29/16WAVE Life Sciences to Present at the Deutsche Bank 41st Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Deutsche Bank 41st Annual Health Care Conference at 3:30 PM EDT on Wednesday, May 4, 2016 in Boston, Mass. About WAVE Life Sciences ... 
Printer Friendly Version
03/30/16WAVE Life Sciences Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update
On track to file two INDs for lead programs in Huntington’s disease in 2016; Advancing over 20 discovery programs for genetically defined rare and other serious diseases Strong financial position; existing cash to support pipeline progression, clinical programs and operations well into 2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 30, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing... 
Printer Friendly Version
02/16/16WAVE Life Sciences to Present at the SunTrust Robinson Humphrey 2016 Orphan Drug Day Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 16, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicine company focused on developing stereopure nucleic acid therapies to deliver new and exceptional treatment options for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the SunTrust Robinson Humphrey 2016 Orphan Drug Day on Tuesday, February 23, 2016 at the JW Marri... 
Printer Friendly Version
02/03/16WAVE Life Sciences to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicine company focused on advancing potential best-in-class stereopure nucleic acid therapies, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY. ... 
Printer Friendly Version
01/29/16WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018
Company outlines strategy to become genetic medicine leader Over 20 stereopure antisense, exon skipping, and RNAi programs in early discovery and development across multiple therapeutic areas that have the potential to be best-in-class Development efforts focused on neurological and neuromuscular rare diseases; Company plans to file INDs for lead programs in Huntington’s disease by end of 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-... 
Printer Friendly Version